Tuesday, 16 April, 2024

27 Jun 2014 | Press Release

news > News and Events > Page 1

Safe strep throat vaccine closer to reality

Infection Control

Researchers are one step closer to developing a safe vaccine against strep throat, which is responsible for more than 700 million infections and 500,000 deaths each year.


A study by an international team, including scientists from The University of Queensland, has shed new light on how Group A Streptococcus (strep) bacteria resists the human immune system.

The research could eventually lead to the development of a safe vaccine against strep throat, necrotising fasciitis (flesh-eating disease) and rheumatic heart disease.

UQ School of Chemistry and Molecular Biosciences researcher and co-lead author of the study, Dr Jason Cole, said previous efforts to develop a strep throat vaccine had resulted in immune system reactions that caused other diseases such as rheumatic fever and heart damage.

“We have discovered genes that make up the cell wall of the strep bacteria, which is composed mainly of the group A carbohydrate or GAC,” he said.

The group A carbohydrate was previously thought to play a largely structural role in the bacteria cell walls.

“We have now confirmed that it actually plays a critical role in how the bacteria resist the immune response.

“This may trigger diseases such as rheumatic heart disease, which has hindered the development of a safe vaccine.

“Based on this information, we are now able to produce a modified group A carbohydrate for further vaccine studies, avoiding previous safety concerns associated with a strep vaccine."

The study, published online in Cell Host & Microbe, was led by Professor Victor Nizet of the University of California, San Diego (UCSD).

UQ researchers led by Professor Mark Walker, from the School of Chemistry and Molecular Biosciences, in collaboration with Emory University and UCSD in the United States, are now undertaking further pre-clinical testing of the modified vaccine.

Professor Walker said the pre-clinical trials were designed to demonstrate that the vaccine was safe and effective before proceeding to human clinical trials.

The research received funding from the UCSD Program in Excellence in Glycosciences, the Australian National Health and Medical Research Council, the Wellcome Trust and the Netherlands Organization for Scientific Research.

Related Contacts

Techniques

From the editor

Surgery Design

Abstracts

Stream the latest dental videos...
Preparing Your Business Recovery Plan

Sponsored Links...

Upcoming Events...

Apr 16 2024

Dentists Behaving 'Very' Badly

Brisbane, AUSTRALIA

Apr 19 2024
Apr 19 2024

IDEM Singapore 2024

Singapore, SINGAPORE

Apr 23 2024
Apr 24 2024
May 01 2024
May 02 2024
May 09 2024
May 11 2024
May 14 2024
May 22 2024
May 24 2024
May 29 2024
May 30 2024
May 31 2024

Scottish Dental Show 2024

Glasgow, UNITED KINGDOM

May 31 2024

Famdent Show Mumbai 2024

Mumbai, INDIA

Jun 01 2024
Jun 06 2024
Jun 09 2024
Jun 11 2024
Jun 22 2024
Jul 13 2024
Jul 16 2024
Jul 25 2024
Aug 23 2024
Aug 29 2024

Practical Endodontics Workshop

Sydney, AUSTRALIA

Sep 07 2024
Sep 14 2024
Sep 26 2024
Oct 03 2024
Oct 10 2024
Oct 17 2024

ADOHTA 2024 National Congress

Sydney, AUSTRALIA

Oct 24 2024
Nov 13 2024
Nov 29 2024
Mar 25 2025

IDS 2025

Cologne, GERMANY

May 08 2025